(CNMD) CONMED - Ratings and Ratios
Surgical Instruments, Endoscopes, Monitoring
CNMD EPS (Earnings per Share)
CNMD Revenue
Description: CNMD CONMED
CONMED Corporation is a US-based healthcare equipment company, operating in the healthcare sector. The companys stock performance is characterized by a current price of $52.48, indicating a potential undervaluation given its historical 52-week high of $76.77 and low of $47.49.
To evaluate the companys financial health, key performance indicators (KPIs) such as Return on Equity (RoE) and Price-to-Earnings (P/E) ratio are crucial. CONMEDs RoE stands at 11.37%, suggesting a relatively stable return for shareholders. The P/E ratio is 15.44, which is lower than the forward P/E of 27.03, indicating potential growth expectations.
The healthcare equipment industry is driven by factors such as aging population demographics, increasing demand for surgical procedures, and advancements in medical technology. CONMEDs market capitalization of $1.69 billion positions it as a mid-cap company, potentially offering a balance between growth and stability. The companys beta of 1.173 suggests a slightly higher volatility compared to the overall market, which may be attributed to its industry and market dynamics.
To further assess the companys prospects, examining its income tax expense on a yearly basis can provide insights into its tax management and profitability. A thorough analysis of CONMEDs financial statements, including its income statement, balance sheet, and cash flow statement, would be necessary to identify trends, opportunities, and challenges.
Economic drivers influencing CONMEDs performance include healthcare spending trends, regulatory changes, and technological innovations. The companys ability to adapt to these factors and maintain a competitive edge will be crucial in determining its future stock performance.
CNMD Stock Overview
| Market Cap in USD | 1,635m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1987-07-23 |
CNMD Stock Ratings
| Growth Rating | -72.4% |
| Fundamental | 60.5% |
| Dividend Rating | 33.3% |
| Return 12m vs S&P 500 | -41.1% |
| Analyst Rating | 3.33 of 5 |
CNMD Dividends
| Dividend Yield 12m | 1.44% |
| Yield on Cost 5y | 1.01% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 96.4% |
| Payout Ratio | 19.9% |
CNMD Growth Ratios
| Growth Correlation 3m | 47.5% |
| Growth Correlation 12m | -84.9% |
| Growth Correlation 5y | -74.6% |
| CAGR 5y | -15.88% |
| CAGR/Max DD 3y | -0.25 |
| CAGR/Mean DD 3y | -0.39 |
| Sharpe Ratio 12m | -1.00 |
| Alpha | -38.97 |
| Beta | 0.399 |
| Volatility | 40.00% |
| Current Volume | 313k |
| Average Volume 20d | 312k |
| Stop Loss | 49.9 (-3.6%) |
| Signal | -1.91 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (110.2m TTM) > 0 and > 6% of Revenue (6% = 79.7m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.33% (prev 28.05%; Δ -0.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 165.2m > Net Income 110.2m (YES >=105%, WARN >=100%) |
| Net Debt (847.9m) to EBITDA (188.4m) ratio: 4.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (31.1m) change vs 12m ago -0.17% (target <= -2.0% for YES) |
| Gross Margin 56.12% (prev 53.97%; Δ 2.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.57% (prev 55.74%; Δ 1.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.92 (EBITDA TTM 188.4m / Interest Expense TTM 34.2m) >= 6 (WARN >= 3) |
Altman Z'' 2.63
| (A) 0.16 = (Total Current Assets 657.8m - Total Current Liabilities 294.8m) / Total Assets 2.33b |
| (B) 0.25 = Retained Earnings (Balance) 575.4m / Total Assets 2.33b |
| (C) 0.06 = EBIT TTM 134.2m / Avg Total Assets 2.31b |
| (D) 0.39 = Book Value of Equity 522.7m / Total Liabilities 1.33b |
| Total Rating: 2.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.54
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 5.97% = 2.99 |
| 3. FCF Margin 11.16% = 2.79 |
| 4. Debt/Equity 0.88 = 2.13 |
| 5. Debt/Ebitda 4.68 = -2.50 |
| 6. ROIC - WACC 0.70% = 0.87 |
| 7. RoE 11.37% = 0.95 |
| 8. Rev. Trend 81.18% = 4.06 |
| 9. Rev. CAGR 8.28% = 1.03 |
| 10. EPS Trend 8.83% = 0.22 |
| 11. EPS CAGR -24.31% = -2.50 |
What is the price of CNMD shares?
Over the past week, the price has changed by -3.42%, over one month by -2.13%, over three months by -2.61% and over the past year by -29.96%.
Is CONMED a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNMD is around 41.69 USD . This means that CNMD is currently overvalued and has a potential downside of -19.5%.
Is CNMD a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CNMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61 | 17.8% |
| Analysts Target Price | 61 | 17.8% |
| ValueRay Target Price | 45.1 | -13% |
Last update: 2025-09-11 04:35
CNMD Fundamental Data Overview
CCE Cash And Equivalents = 33.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.9181
P/E Forward = 27.027
P/S = 1.2326
P/B = 1.6662
P/EG = 5.29
Beta = 1.186
Revenue TTM = 1.33b USD
EBIT TTM = 134.2m USD
EBITDA TTM = 188.4m USD
Long Term Debt = 881.1m USD (from longTermDebt, last quarter)
Short Term Debt = 714.0k USD (from shortTermDebt, last quarter)
Debt = 881.8m USD (Calculated: Short Term 714.0k + Long Term 881.1m)
Net Debt = 847.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.48b USD (1.63b + Debt 881.8m - CCE 33.9m)
Interest Coverage Ratio = 3.92 (Ebit TTM 134.2m / Interest Expense TTM 34.2m)
FCF Yield = 5.97% (FCF TTM 148.2m / Enterprise Value 2.48b)
FCF Margin = 11.16% (FCF TTM 148.2m / Revenue TTM 1.33b)
Net Margin = 8.30% (Net Income TTM 110.2m / Revenue TTM 1.33b)
Gross Margin = 56.12% ((Revenue TTM 1.33b - Cost of Revenue TTM 582.8m) / Revenue TTM)
Tobins Q-Ratio = 4.75 (Enterprise Value 2.48b / Book Value Of Equity 522.7m)
Interest Expense / Debt = 0.89% (Interest Expense 7.82m / Debt 881.8m)
Taxrate = 18.77% (30.6m / 163.0m)
NOPAT = 109.0m (EBIT 134.2m * (1 - 18.77%))
Current Ratio = 2.23 (Total Current Assets 657.8m / Total Current Liabilities 294.8m)
Debt / Equity = 0.88 (Debt 881.8m / last Quarter total Stockholder Equity 1.00b)
Debt / EBITDA = 4.68 (Net Debt 847.9m / EBITDA 188.4m)
Debt / FCF = 5.95 (Debt 881.8m / FCF TTM 148.2m)
Total Stockholder Equity = 969.0m (last 4 quarters mean)
RoA = 4.73% (Net Income 110.2m, Total Assets 2.33b )
RoE = 11.37% (Net Income TTM 110.2m / Total Stockholder Equity 969.0m)
RoCE = 7.25% (Ebit 134.2m / (Equity 969.0m + L.T.Debt 881.1m))
RoIC = 5.81% (NOPAT 109.0m / Invested Capital 1.87b)
WACC = 5.12% (E(1.63b)/V(2.52b) * Re(7.49%)) + (D(881.8m)/V(2.52b) * Rd(0.89%) * (1-Tc(0.19)))
Shares Correlation 3-Years: -13.74 | Cagr: -0.01%
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.91% ; FCFE base≈152.6m ; Y1≈159.4m ; Y5≈184.4m
Fair Price DCF = 104.6 (DCF Value 3.24b / Shares Outstanding 31.0m; 5y FCF grow 4.74% → 3.0% )
Revenue Correlation: 81.18 | Revenue CAGR: 8.28%
Rev Growth-of-Growth: -7.68
EPS Correlation: 8.83 | EPS CAGR: -24.31%
EPS Growth-of-Growth: -29.90
Additional Sources for CNMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle